Background: Myocardial infarction (MI) patients are increasingly older, and common risk scores include chronological age, but do not consider chronic comorbidity or biological age. Frailty status reflects these variables and may be independently correlated with prognosis in this setting. Objective: This study investigated the impact of frailty on the prognosis of elderly patients admitted due to MI. Methods: This prospective and observational study included patients ≥75 years admitted to three tertiary hospitals in Spain due to MI. Frailty assessment was performed at admission using the Survey of Health, Ageing and Retirement in Europe Frailty Index (SHARE-FI) tool. The primary endpoint was the composite of death or non-fatal reinfarction during a follow-up of 1 year. Overall mortality, reinfarction, the composite of death, reinfarction and stroke, major bleeding, and readmission rates were also explored. Results: A total of 285 patients were enrolled. Frail patients (109, 38.2%) were older, with a higher score in the Charlson Comorbidity Index and with a higher risk score addressed in the GRACE and CRUSADE indexes. On multivariate analysis including GRACE, CRUSADE, maximum creatinine level, culprit lesion revascularization, complete revascularization, and dual antiplatelet therapy at discharge, frailty was an independent predictor of the composite of death and reinfarction (2.81, 95% CI 1.16–6.78) and overall mortality (3.07, 95% CI 1.35–6.98). Conclusion: Frailty is an independent prognostic marker of the composite of mortality and reinfarction and of overall mortality in patients aged ≥75 years admitted due to MI.

Keywords:
Frailty, Cardiovascular disease, Cardiology, Ageing, Prognosis
1.
Dégano IR, Elosua R, Marrugat J: Epidemiology of acute coronary syndromes in Spain: estimation of the number of cases and trends from 2005 to 2049. Rev Esp Cardiol (Engl Ed) 2013; 66: 472–481.
2.
Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Circulation 2007; 116: 2634–2653.
3.
Alexander KP, Newby LK, Cannon CP, et al; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology: Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115: 2549–2569.
4.
Alexander KP, Newby LK, Armstrong PW, et al; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology: Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115: 2570–2589.
5.
Alegre O, Ariza-Solé A, Vidán MT, et al: Impact of frailty and other geriatric syndromes on clinical management and outcomes in elderly patients with non-ST-segment elevation acute coronary syndromes: rationale and design of the LONGEVO-SCA Registry. Clin Cardiol 2016; 39: 373–377.
6.
Fried LP, Tangen CM, Walston J, et al; Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146–M156.
7.
Romero-Ortuno R, Walsh CD, Lawlor BA, et al: A frailty instrument for primary care: findings from the Survey of Health, Ageing and Retirement in Europe (SHARE). BMC Geriatr 2010; 10: 57.
8.
Mehta SR, Granger CB, Boden WE, et al: Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360: 2165–2175.
9.
Subherwal S, Bach RG, Chen AY, et al: Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation 2009; 119: 1873–1882.
10.
Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
11.
Katz S, Downs TD, Cash HR, et al: Progress in development of the index of ADL. Gerontologist 1970; 10: 20–30.
12.
Ekerstad N, Swahn E, Janzon M, et al: Frailty is independently associated with 1-year mortality for elderly patients with non-ST-segment elevation myocardial infarction. Eur J Prev Cardiol 2014; 21: 1216–1224.
13.
Ekerstad N, Swahn E, Janzon M, et al: Frailty is independently associated with short-term outcomes for elderly patients with non-ST segment elevation myocardial infarction. Circulation 2011; 124: 2397–2404.
14.
White HD, Westerhout CM, Alexander KP, et al: Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial–. Eur Heart J Acute Cardiovasc Care 2016; 5: 231–242.
15.
Sujino Y, Tanno J, Nakano S, et al: Impact of hypoalbuminemia, frailty, and body mass index on early prognosis in older patients (≥85 years) with ST-elevation myocardial infarction. J Cardiol 2015; 66: 263–268.
16.
Ariza-Solé A, Formiga F, Vidán MT, et al: Impact of frailty and functional status on outcomes in elderly patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: rationale and design of the IFFANIAM study. Clin Cardiol 2013; 36: 565–569.
17.
Alonso Salinas GL, Sanmartín-Fernández M, Pascual Izco M, et al: Frailty is a short-term prognostic marker in acute coronary syndrome of elderly patients. Eur Heart J Acute Cardiovasc Care 2016; 5: 434–440.
18.
Graham MM, Galbraith PD, O’Neill D, et al: Frailty and outcome in elderly patients with acute coronary syndrome. Can J Cardiol 2013; 29: 1610–1615.
19.
Sanchis J, Bonanad C, Ruiz V, et al: Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrome. Am Heart J 2014; 168: 784–791.
20.
Lisiak M, Uchmanowicz I, Wontor R: Frailty and quality of life in elderly patients with acute coronary syndrome. Clin Interv Aging 2016; 11: 553–562.
21.
Alonso Salinas GL, Sanmartín Fernández M, Pascual Izco, et al: Frailty predicts major bleeding within 30 days in elderly patients with acute coronary syndrome. Int J Cardiol 2016; 222: 590–593.
22.
Klein LW, Arrieta-Garcia C: Is patient frailty the unmeasured confounder that connects subacute stent thrombosis with increased periprocedural bleeding and increased mortality? J Am Coll Cardiol 2012; 59: 1760–1762.
23.
Kang L, Zhang SY, Zhu WL, et al: Is frailty associated with short-term outcomes for elderly patients with acute coronary syndrome? J Geriatr Cardiol 2015; 12: 662–667.
24.
Alonso Salinas GL, Sanmartin M, Pascual Izco M, et al: Frailty is an independent prognostic marker in elderly patients with myocardial infarction. Clin Cardiol 2017; 40: 925–931.
25.
Libungan B, Karlsson T, Hirlekar G, et al: Delay and inequality in treatment of the elderly with suspected acute coronary syndrome. Int J Cardiol 2014; 176: 946–950.
26.
Tegn N, Abdelnoor M, Aaberge L, et al: Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet 2016; 387: 1057–1065.
27.
Ma W, Liang Y, Zhu J: Early invasive versus initially conservative strategy in elderly patients older than 75 years with non-ST-elevation acute coronary syndrome: a meta-analysis. Heart Lung Circ 2018; 27: 611–620.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.